학술논문
Phase II, Open-label, Single-arm, Multicenter Study to Assess the Activity and Safety of Alectinib as Neoadjuvant Treatment in Surgically Resectable Stage III ALK-positive NSCLC: ALNEO Trial
Document Type
Article
Author
Source
In: Clinical Lung Cancer . (Clinical Lung Cancer, September 2021, 22(5):473-477)
Subject
Language
English
ISSN
19380690
15257304
15257304